Who is sponsoring NCT04706949?

NCT04706949 is sponsored by Fudan University.

What condition does NCT04706949 study?

NCT04706949 studies Lung Cancer, Non-small Cell.

Is NCT04706949 still recruiting?

NCT04706949 is currently status unknown. Last updated 13 January 2021.

Last reviewed 2021-01-13 · How we verify

NCT04706949

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment

Status unknown Phase 2 Last updated 13 January 2021

What this trial tests

Phase 2 trial testing Pyrotinib combined with pemetrexed plus carboplatin in Lung Cancer, Non-small Cell in 26 participants. Status unknown.

Timeline

7 December 2020

Primary endpoint
31 December 2021

31 December 2022

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	7 December 2020
Primary completion	31 December 2021
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

Pyrotinib combined with pemetrexed plus carboplatin — full drug profile →

Conditions studied

Lung Cancer, Non-small Cell — all drugs for Lung Cancer, Non-small Cell →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with Lung Cancer, Non-small Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, single center, single arm, phase II clinical trial of Pyrotinib combined with pemetrexed plus carboplatin in the first-line treatment of patients with HER2 mutant or amplified recurrent / metastatic non-small cell lung cancer

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities.
Ismail A, Desai A, Boumber Y. · · 2025 · cited 6× · PMID 40620714 · DOI 10.3389/fonc.2025.1624124
[Advances in Targeted Therapy for Advanced Non-small Cell Lung Cancer  with HER2 Mutation].
Yu J, Cao B. · · 2025 · PMID 41158042 · DOI 10.3779/j.issn.1009-3419.2025.106.22

Verify or expand the search:

Other recruiting trials for Lung Cancer, Non-small Cell

Currently open trials in the same condition.

NCT06538012 — TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer · Phase 1, PHASE2 · recruiting
NCT04940936 — Shared Decision Making on Radiation Dose for Lung Malignancies · NA · recruiting
NCT05598528 — Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Adv · recruiting
NCT04986670 — NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer · NA · active not recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04706949 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 13 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04706949.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing